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Tuberculosis is the primary infectious disease killer worldwide, with a growing threat from multidrug-resistant cases. Unfortunately, 
classic growth-based phenotypic drug susceptibility testing (DST) remains difficult, costly, and time consuming, while current 
rapid molecular testing options are limited by the diversity of antimicrobial-resistant genotypes that can be detected at once. Next-
generation sequencing (NGS) offers the opportunity for rapid, comprehensive DST without the time or cost burden of phenotypic 
tests and can provide useful information for global surveillance. As access to NGS expands, it will be important to ensure that results 
are communicated clearly, consistent, comparable between laboratories, and associated with clear guidance on clinical interpretation 
of results. In this viewpoint article, we summarize 2 expert workshops regarding a standardized report format, focusing on relevant 
variables, terminology, and required minimal elements for clinical and laboratory reports with a proposed standardized template for 
clinical reporting NGS results for Mycobacterium tuberculosis.
Keywords. tuberculosis; next-generation sequencing; reporting; standardization; interpretation.
Tuberculosis is a critical global health concern, with an estimated 
10 million new cases in 2017, including approximately 460 000 
multidrug-resistant (MDR) cases (resistant to isoniazid and ri-
fampin) [1]. MDR-tuberculosis rates are estimated to rise in 4 
high-burden countries due to ongoing transmission, raising the 
stakes on identification and resistance profiling of new cases 
[2]. While culture-based phenotyping remains the reference 
standard for drug susceptibility testing (DST), the paradigm has 
shifted recently with the World Health Organization (WHO) 
endorsement and global implementation of molecular assays 
such as Cepheid Xpert® MTB/RIF [3] and line-probe assays 
[4, 5] that provide rapid DST results without the time or cost 
burden of phenotypic testing. While transformative, existing 
rapid molecular tests are limited by the diversity of resistant 
genotypes that can be detected simultaneously. Whole-genome 
sequencing (WGS) and targeted DNA sequencing directly 
from clinical samples offer potential comprehensive solutions 
for rapid diagnosis, DST, and large-scale drug-resistance sur-
veillance [6–8]. In 2017, Public Health England implemented 
WGS for all mycobacterial cultures, and the United States 
announced plans for universal WGS surveillance, while New 
York State’s Wadsworth Center has incorporated WGS since 
2016 [9–11]. The European Centre for Disease Prevention 
and Control is also standardizing WGS across the 28 member 
states to monitor cross-border transmission, and WHO has 
led multicountry population-level surveys to determine the 
best use of next-generation sequencing (NGS) and DST world-
wide, laying the groundwork for widespread access [8, 12, 13]. 
Current sequencing programs often rely on centralized govern-
ment or academic facilities due to the need for specially skilled 
laboratorians, infrastructure, data management capacity, and 
bioinformatics. Efforts to overcome these obstacles and aid 
broader NGS deployment are underway and will likely provide 
global access to DNA sequencing technologies for clinical diag-
nosis of drug-resistant tuberculosis in the next 5 years [14–17].
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Increasing global reliance on molecular assays for tubercu-
losis requires improved laboratory reporting language to ensure 
that results are communicated clearly, consistently, and com-
parably across laboratories and are associated with interpreta-
tive guidance for clinical decision making. Such a framework 
would help standardize implementation of effective treatment 
guidelines and improve confidence in results [18]. Although 
several institutions have implemented individualized NGS re-
porting schemes, a globally developed framework for clinical 
reporting of molecular DST results for Mycobacterium tubercu-
losis (Mtb) is needed to standardize interpretation and clinical 
application worldwide. The TBNET and RESIST-TB networks 
have provided perspectives on reporting standards, including 
a review of common mutations, associations with resistance, 
endorsement of specific mutations to report, and interpretative 
guidance to help select effective treatment [19, 20]. Additional 
efforts such as the Relational Sequencing TB Data Platform 
(ReSeqTB) [21] are standardizing analytic and interpreta-
tive criteria for drug-resistance determining mutations, and 
WHO recently released a technical guide on NGS for Mtb [22]. 
However, a harmonized reporting format is essential to ensure 
that patients across the globe reap similar benefits from the 
same sequencing results.
To address this need, the Critical Path Institute (C-Path) 
in collaboration with WHO and the US National Institutes of 
Health, Division of AIDS, National Institute of Allergy and 
Infectious Diseases, convened a workshop in London, United 
Kingdom, 3–4 February 2016, followed by a second work-
shop cosponsored by C-Path and FIND diagnostics on 27–28 
September 2017. The objectives were to produce a proposed 
standardized reporting format and to define comprehensive 
and minimal data elements to include in clinical and laboratory 
reports of NGS data. In this Viewpoint article, we describe key 
discussion points and consensus outcomes regarding clinical 
reporting of NGS-derived molecular DST results for Mtb.
CHALLENGES AND OPPORTUNITIES FOR 
MOLECULAR DST
Diagnostic devices that incorporate genomics are increasingly 
being deployed globally. A recent publication showed that WGS 
can predict antimicrobial resistance to first-line drugs with 
high sensitivity that, if confirmed, will likely reduce phenotypic 
testing in low-burden countries [23]. In addition, sequence data 
provide richer information than the categorical “susceptible” vs 
“resistant” clinical results most often reported from molecular 
diagnostics. Thus, sequence data have the potential to be used 
for quantitative interpretations (eg, as needed for transmission 
tracking or identifying heteroresistance) and more nuanced 
clinical conclusions (eg, specific mutations associated with spe-
cific elevations in minimum inhibitory concentration [MIC]), 
which could ultimately enable more sophisticated treatment 
decision support. NGS pipelines, including the ReSeqTB data 
platform and PhyResSE, are standardizing the bioinformatics 
approaches and catalogues of confidence-graded resistance-
associated mutations required for molecular DST. However, 
even the best assays can still produce discordant results between 
molecular and growth-based DST [21, 24, 25]. Challenges in-
clude an evolving consensus on specific loci of interest, a con-
stantly improving knowledge base for associating detected 
mutations with drug resistance, variable numbering systems 
for relevant genes, assay limits of detection, interpretation of 
heteroresistance, limited bioinformatics capacity in the regions 
of highest need, and lack of a global reporting standard.
Although most drug-resistance mechanisms are well 
documented for Mtb, several knowledge gaps remain. WGS 
can be used to evaluate substantially more loci than polymerase 
chain reaction assay or targeted sequencing, and accurate sus-
ceptibility prediction for each mutation requires a large dataset 
of isolates with comprehensive phenotypic DST. As a result, it 
is difficult to reliably associate drug resistance with uncommon 
mutations, insertions and deletions (indels), and mutations that 
affect drugs for which susceptibility is rarely tested. In addi-
tion, there is no standard nomenclature for mutation reporting 
in infectious disease microbiology, complicating reports for 
genes such as rpoB that have distinct numbering systems for 
Escherichia coli and Mtb. Use of a consensus numbering system 
would ensure consistent interpretation of these mutations [26]. 
Uniform standards such as those used by molecular pathology 
and medical genetics organizations could help improve clarity 
of Mtb reporting [27–30].
Even when these problems are resolved, NGS-based DST will 
still require significant bioinformatic programming written and 
maintained by highly trained staff. Automated, cloud-based 
platforms such as PhyResSE and ReSeqTB have integrated 
unified variant pipelines for use by laboratories with less bio-
informatics expertise in order to generate variant reports with 
clinical interpretation [21, 25]. Similar WGS pipelines could be 
developed to analyze lineage and strain relatedness for molec-
ular epidemiology studies, transmission mapping, and iden-
tification of potential outbreaks, especially in low-incidence 
settings such as the pipeline used by Public Health England 
[31]. While these online services are still being developed for 
full public access, they are positioned to transform the analysis 
of NGS data and democratize the utility of this technology for 
nonexpert use.
As NGS becomes widespread in programmatic 
environments worldwide [23], a global standard for recording, 
reporting, and interpreting these data must grow in parallel, 
so that globally representative data can be collated for both 
DST and surveillance purposes [8]. Effective clinical imple-
mentation of NGS should classify mutations using a robust 
statistical approach in order to understand the predictive 
value for drug resistance as determined by correlation with 
growth-based DST results and, ideally, clinical outcomes. This 
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should align with standardized reporting efforts to generate 
reports that healthcare providers and public health programs 
can easily understand. For Mtb, a standardized classification 
scheme for clinically grading mutations in Mtb was proposed 
using likelihood ratios, similar to clinical decision-making 
tools used in evidence-based medicine [20]. However, the 
value of mutation grading schemes will greatly depend on 
the quality of the dataset used for these calculations and 
the frequency of mutations in that dataset. The addition of 
MIC ranges to resistance prediction could also aid health-
care providers in clinical management. Highly curated, dy-
namic databases such as ReSeqTB [21] and projects such as 
the Comprehensive Resistance Prediction for Tuberculosis: an 
International Consortium [23, 32] generate high-quality phe-
notypic and WGS data for large numbers of well-characterized 
isolates. Ideally, a laboratory report could leverage these large 
datasets to interpret and classify mutations identified in clin-
ical samples in order to allow healthcare providers to devise 
effective treatment regimens. Initiatives to develop inter-
operable database ontologies for consolidating drug resist-
ance in Mtb will allow reports to be updated as datasets are 
standardized and integrated to interpret additional mutations 
and improve confidence in resistance predictions over time.
DEVELOPMENT OF STANDARDIZED REPORTS
A standardized format and nomenclature for reporting 
NGS results must balance simplicity and clarity while pro-
viding the necessary data required by healthcare providers, 
country-level surveillance programs, and stringent regula-
tory authorities that seek to regulate NGS as an in vitro di-
agnostic. The report should be flexible to the needs of users 
with different training levels, with a simple summary, ad-
ditional details for expert users, and a flexible structure to 
grow as resistance-predicting datasets expand. To meet these 
needs, the authors designed example laboratory reports in 
consultation with the February 2016 workshop participants 
and circulated them to dozens of stakeholders worldwide. 
After multiple revisions, report templates were presented at 
the September 2017 workshop.
Meeting participants included researchers, laboratorians, 
NGO representatives, clinicians, bioinformaticians, 
epidemiologists, government representatives, and public health 
workers, with representatives from Europe, North and South 
America, Southeast Asia, Africa, and the Western Pacific. 
A live polling tool incorporated participants’ feedback on each 
data element, which was combined with design study research 
principles to generate these reports [33]. A  strong preference 
emerged for a laboratory report that healthcare providers and 
laboratorians with a range of education levels and expertise 
could use for clinically relevant drug-resistance prediction. 
Meeting participants discussed that molecular epidemiology 
data would be desirable in some circumstances, but including 
transmission cluster analysis was not identified as a priority for 
the report template given the focus on drug resistance. The in-
tended purpose of these reports is to provide information that 
is useful for healthcare providers in determining optimal treat-
ment regimens. Workshop participants concluded that results 
should be presented as 2 reports: a 1-page simplified report for 
healthcare providers and laboratorians with less expertise in 
NGS and a longer-form report for providing data on a compre-
hensive set of NGS variables.
Proposed Reporting Formats
Each patient sample that is sequenced generates 2 parallel 
reports. The first represents a summary document with a lim-
ited, basic representation of the high-confidence resistance-
associated mutations identified (Figure 1). The second, longer 
report includes the same high-confidence mutations but adds 
nuanced data, including lower-confidence mutations and tech-
nical details so that more experienced users can troubleshoot 
complex cases (Figure 2 and Supplementary Materials). The re-
lationship between reports is demonstrated in Figure 2.
In both reports, resistance interpretations are based on like-
lihood ratios using data from a large globally representative 
database, in this case the ReSeqTB database [34]. Each resist-
ance interpretation incorporates a confidence statement as 
described in the Disclaimer section of the comprehensive re-
port (Supplementary Materials). Mutations that reach min-
imum confidence thresholds are included in both reports, 
which are adaptable to meet programmatic needs and could be 
amended to include an expanded set of loci, drugs, or different 
methodologies for defining interpretative criteria. The expecta-
tion is that as datasets grow and confidence statements become 
available for loci that impact new and repurposed drugs, such 
mutations, initially reported only in the comprehensive report 
due to limited confidence, would eventually be presented in the 
simple, 1-page report, provided in parallel, along with all other 
high-confidence resistance predications.
The 1-page report (Figure 1) summarizes mutations with 
a high likelihood of association with first- and second-line 
drug resistance, referring readers for expert consultation for 
pyrazinamide and moxifloxacin in the case of mutations with 
less clear treatment interpretations (Figure 2). Both reports 
include a Sample Details section with the minimal set of data 
elements, including relevant patient demographics, the labora-
tory that performed the test, requestor, specimen type, source, 
and collection date, the report date, a unique sample ID and a 
barcode associated with the submission, followed by an Assay 
Details section with information regarding methodology. 
Assay Details includes the sequencing methodology (eg, WGS 
or targeted sequencing), instrumentation used, analytic pipe-
line and version, and the reference genome. The Final Result 
section consists of an easy-to-locate, plain-language summary 
regarding Mtb identification and predicted drug resistance. In 
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the example provided, the sample was positive for Mtb with 
mutations predicted to cause phenotypic resistance to isoniazid, 
rifampin, capreomycin, kanamycin, ofloxacin/levofloxacin, and 
moxifloxacin. Additional information regarding lineage and 
drug susceptibility results are provided in the latter sections of 
the report. 
Preference was given to include the complete drug name instead 
of abbreviations. Each drug for which a gene target was evaluated 
Figure 1. One-page M. tuberculosis sequencing summary report to assist in making clinical decisions for patient management.
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is included with a categorical interpretation (resistant, susceptible, 
low-level resistance or intermediate, expert consultation advised, 
unclassified, or failure of the test to evaluate a particular drug due 
to low coverage at that site). Where the test failed or only specific 
loci were evaluated, the categorical results for interpretation might 
be “assay failed,” “unsuccessfully evaluated,” or “no test results.” All 
gene targets evaluated should be included and provide the spe-
cific nucleotide change and position(s) or amino acid change(s) 
using the 3-letter abbreviation with its associated codon, as appli-
cable, along with the frequency of the reported mutation among 
the reads examined (ie, allele %). The Mtb genomic position 
numbering system should be used (rather than E. coli numbering) 
to avoid confusion. Workshop participants did not define a spe-
cific threshold for a resistant allele to be reported since this will 
differ depending on the gene of interest, the sequencing chemistry 
used, and the sequencing technology used. Indels are indicated in 
the report with the specific insertion or deletion provided. 
The Comments column of the Drug Susceptibility section 
provides additional details including an indication that “expert 
consultation advised,” when molecular results indicate a more 
complicated interpretation (eg, heteroresistance, conflicting in 
vitro data, low-level resistance conferring mutations, or failure 
to sequence a specific gene target). Workshop participants in-
dicated that the simplified report should focus on providing 
information for high-confidence mutations only, with recom-
mendation for consultation whenever results with a more am-
biguous interpretation are encountered.
The comprehensive report (Supplementary Materials) 
contains all information from the 1-page report but provides 
additional details including mutations with less defini-
tive interpretations. This report would be relevant to expert 
laboratorians, researchers, and healthcare providers who could 
interpret complex sequencing data in order to clarify ambig-
uous or uncommon results when expert consultation was ad-
vised, including lower confidence mutations, mutations in loci 
of interest with insufficient data to generate a resistance predic-
tion, and depth and coverage statistics to contextualize findings 
(Figure 2). In contrast to the 1-page report in which only high-
confidence mutations are reported, all identified mutations are 
presented as confidence graded, showing association with re-
sistance provided by the likelihood ratio. In the example pro-
vided (Figure 2), the pncA mutation T416C (amino acid change 
Val139Ala) is listed in the expanded report with a comment that 
although the mutation is known to disrupt pyrazinimidase ac-
tivity, insufficient data are available to determine clinical impact 
on pyrazinamide use. In addition, some rare mutations may be 
more prevalent in certain geographical settings where local ex-
pertise may be used to contribute to the body of knowledge. This 
level of detail was not provided in the 1-page report and would 
allow the expert adjudicator to confirm pyrazinamide drug re-
sistance. Additionally, the expanded report would specify resist-
ance predictions with reference to different test concentrations. 
In Figure 2, the gyrA C269T (Ala90Val) mutation is reported 
as a high-confidence mutation. However, an interpretation of 
Figure 2. Detailed multi-page M. tuberculosis laboratory sequencing report containing additional information to aid in interpretation through expert consultation. 
Abbreviation: NGS, next-generation sequencing.
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intermediate resistance and a comment indicating that at least 
low-level phenotypic resistance is predicted (≥0.5  μg/mL in 
liquid culture) suggest the potential to use a higher fluoroquin-
olone dose to treat the patient [35]. Workshop participants felt 
that making this level of information available, when possible, 
for laboratory reporting would be critical for aiding clinical de-
cision making.
The comprehensive report also includes 2 additional sections. 
The section on “Resistance Predictions for Other TB Drugs” 
provides data for new or repurposed antituberculosis drugs (eg, 
bedaquiline, clofazimine, delamanid, and linezolid). This section 
is intended for informational purposes based on research and 
periodic review of published literature due to the lack of clinical 
corroborations and insufficient culture-based phenotypic data 
for these drugs. Nevertheless, the widespread use of WGS for 
Mtb at the global level is anticipated to provide sufficient data 
in the near future in order to improve the understanding of the 
determinants of resistance for these drugs. Optimally, updates 
to this section after review of new advancements would occur 
through global consensus. However, details regarding this pro-
cess were beyond the scope of workshop objectives. Technical 
information in the Depth and Coverage Details section includes 
information relevant for understanding mutation frequency 
that could aid interpretation during an expert consultation. The 
final Disclaimer section might include relevant performance in-
formation about the methodology used and information about 
statistical tests used to determine confidence of the association 
of mutations to resistance.
NEXT STEPS
Before broadly implementing these standards, the proposed re-
porting format needs to be translated into multiple languages, 
beta tested, and piloted in different use case settings. Gene targets 
included in the report could potentially change and might be de-
termined by scheduled, iterative reviews of databases such as the 
ReSeqTB Data Platform [21, 34]. To guide changes, considera-
tion of loci, interpretative criteria, and confidence levels for each 
mutation’s association with resistance, derived from a systematic 
literature review of correlations with phenotypic susceptibility 
test results, homoplasy, MIC values, functional genetic studies, 
and clinical outcomes, would be appropriate [20]. Governance 
for any structured reviews needs to be established. Although 
a good faith effort has been made to collect broad input, ad-
ditional perspectives from field implementation are crucial to 
ensure usability and frame the terminology in the Comments 
section. Endorsement by entities including WHO would help 
ensure the sustainability of the proposed formats and help stand-
ardize NGS result reporting as access expands in global markets. 
In addition, this proposed model would need to be aligned with 
present and future commercial NGS-based diagnostics. Any 
reporting framework must be accompanied by education and 
training curricula to ensure that laboratorians, clinicians, health-
care workers, epidemiologists, and other stakeholders develop a 
clear understanding of the limitations of testing methodologies, 
the types of information provided, the format, and the inter-
pretive comments. For clinicians, case-based learning is critical 
and should be customized for a range of expertise. Aligning re-
porting with treatment guidelines and clear avenues for expert 
consultation will be crucial. Consideration must also be given 
for combined use of phenotypic and NGS-based DST in settings 
where both are available. Ideally, this reporting framework could 
be incorporated into electronic systems linked with bioinfor-
matic pipelines. Additional modifications may be required for 
this reporting format, but we believe this proposed reporting 
framework for clinical use of NGS data represents a step forward 
with real potential for global acceptance and could be used as a 
template to address antimicrobial resistance for other pathogens.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the author to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the author, so 
questions or comments should be addressed to the corresponding author.
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